Accu-Chek Solo micropump
Roche Diabetes Care
What it is
A small, flat, tubeless micropump with a wireless controller and interoperable pump clearance. Roche is winding down its Accu-Chek pump consumables — final UK and Ireland orders closed in January 2026, and Roche is discontinuing its Accu-Chek pump consumable range in Australia — and we cannot confirm continued consumable supply in any EU market.
Editorial review: .
Most recent recorded citation date: 2018-07-23. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Reliability: Regulatory clearance and years of selected-market use support basic pump function, though large contemporary outcome datasets are limited.[2]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Discontinued — Roche is winding down Accu-Chek pump consumables; continued EU supply unconfirmedApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 65 × 20 + 60 × 20 + 82 × 20 + 45 × 15 + 45 × 10 + 25 × 15 = 5640; divide by total weight 100. Unrounded weighted result: 56.4.
FDA cleared as an alternate-controller-enabled interoperable insulin pump able to communicate with compatible digitally connected devices.[1]
Regulatory clearance and years of selected-market use support basic pump function, though large contemporary outcome datasets are limited.[2]
Tubeless micropump worn flat on the body, with detachable pump holder/reservoir architecture.[1]
Micropump form factor trades reservoir size for small wearability; capacity is less compelling than larger-capacity patch pumps.[1]
Shrinking fast. Roche stopped supplying Accu-Chek insulin pump consumables in the UK and Ireland (final orders 30 January 2026) and is discontinuing its Accu-Chek pump consumable range in Australia, where the NDSS confirms Roche insulin pump consumables leave the scheme on 30 June 2026 — in both cases directing users to transition to another pump. We have not been able to confirm continued consumable supply from a primary source in any specific EU market, and US commercial availability remains unclear despite FDA clearance. A pump without consumables is not a real option.[3]
The full picture
Solo is easy to miss because it is not a US-mainstream AID brand, but it matters to pump completeness: a tubeless Roche micropump, CE-marked and FDA-cleared as interoperable pump technology. Its weakness is not the basic design; it is ecosystem visibility and uneven market availability compared with Omnipod, Tandem, Medtronic or Ypsomed.
That unevenness is now something worse than unevenness. Roche phased out consumables for its Accu-Chek insulin pumps in the UK and Ireland, with final orders on 30 January 2026, and directed existing users to their clinical team to transition to an alternative pump. Five months later the same thing is happening on the other side of the world: Roche is discontinuing its Accu-Chek pump consumable range in Australia, and the National Diabetes Services Scheme confirms that Roche insulin pump consumables leave the scheme on 30 June 2026. (The nine products the NDSS names are the tubed Accu-Chek range — Spirit cartridges, FlexLink, TenderLink and Rapid-D Link — so read that notice as evidence of Roche's exit from pump consumables in Australia rather than as an itemised list of Solo parts.)
Two national wind-downs in five months is not a distribution quirk, and we could not confirm continued consumable supply from a primary source in any specific EU market. A pump without consumables is not a real option, so we have moved the Solo to discontinued rather than assert continued support we cannot evidence. If Roche documents an EU market where Solo consumables remain on supply, this record should change — but we have not found one, and the FDA clearance does not by itself put a pump, or its reservoirs and infusion assemblies, in anyone's hands.
Sources
- [1]FDA 510(k): Accu-Chek Solo micropump system with interoperable technology (K213134) · Regulatory decision
- [2]Roche receives CE Mark for Accu-Chek Solo micropump system · Manufacturer · 2018-07-23
- [3]Accu-Chek Solo micropump — phase out of Accu-Chek insulin pump consumables in January 2026 (Roche UK) · Manufacturer — Final consumable orders 30 January 2026; UK and Ireland pump users directed to their clinical team to transition.
- [4]Roche insulin pump consumables discontinuation (NDSS, Australia) · Trial registry — Roche insulin pump consumables leave the National Diabetes Services Scheme on 30 June 2026 following Roche's decision to discontinue the range. The nine items the NDSS lists are the tubed Accu-Chek range (Spirit cartridge, FlexLink, TenderLink, Rapid-D Link); the notice does not itemise Solo-specific consumables.